Cite
HARVARD Citation
Lopes, J. et al. (2020). ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Journal for immunotherapy of cancer. 8 (1), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Lopes, J. et al. (2020). ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Journal for immunotherapy of cancer. 8 (1), p. . [Online].